Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

5.260 +0.090 (+1.74%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 01, 2023

Via Benzinga

Why Is Hub Cyber Security (HUBC) Stock Up 30% Today? ↗

December 01, 2023

Hub Cyber Security stock is rising higher on Friday as HUBC investors react to an expanded partnership with Blackswan Technologies.

Via InvestorPlace

Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 01, 2023

Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Thursday.

Via Benzinga

Altimmune Inc. (NASDAQ: ALT) is One of Friday Morning’s Most Active Stocks

December 01, 2023

Via Investor Brand Network

Altimmune's Earnings Outlook ↗

November 06, 2023

Via Benzinga

Preview: Altimmune's Earnings ↗

August 09, 2023

Via Benzinga

Altimmune: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Why Is Altimmune (ALT) Stock Up 43% Today? ↗

December 01, 2023

Altimmune stock is rising higher on Friday with heavy trading of ALT shares after posting positive results form a clinical trial.

Via InvestorPlace

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review ↗

December 01, 2023

Software earnings were strong, while the Fed is shifting toward rate cuts.

Via Investor's Business Daily

Topics Economy Stocks

Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower ↗

December 01, 2023

Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 01, 2023

Via Benzinga

Earnings Preview: Altimmune ↗

May 10, 2023

Via Benzinga

Short Volatility Alert: Altimmune Inc ↗

April 21, 2023

On Thursday, shares of Altimmune Inc (NASDAQ: ALT) experienced volatile short activity. After the activity, the stock price went down -4.02% to $5.73. The overall sentiment for ALT has been Bearish.

Via Benzinga

7 Analysts Have This to Say About Altimmune ↗

March 31, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

December 01, 2023

It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers on Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 30, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 26, 2023

Wednesday saw 59 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 18, 2023

During Tuesday's trading, 46 companies set new 52-week lows.

Via Benzinga

5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies ↗

June 20, 2023

Via Benzinga

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It ↗

June 14, 2023

Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise.

Via Benzinga

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy ↗

April 28, 2023

Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023

Via InvestorPlace

7 Biotech Stocks With Huge Return Potential for Long-Term Investors ↗

April 26, 2023

Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 19, 2023

Via Benzinga

7 Cheap Stocks That Are Worth Your Attention ↗

April 03, 2023

Finding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field.

Via InvestorPlace

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion ↗

March 30, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome...

Via Benzinga

Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%? ↗

March 29, 2023

Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.

Via The Motley Fool

Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data

March 28, 2023

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

Via MarketBeat

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Altimmune, Inc. - Common Stock (NQ:ALT)

All News about Altimmune, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today